194 related articles for article (PubMed ID: 29721373)
1. CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.
Leuci V; Casucci GM; Grignani G; Rotolo R; Rossotti U; Vigna E; Gammaitoni L; Mesiano G; Fiorino E; Donini C; Pisacane A; Ambrosio LD; Pignochino Y; Aglietta M; Bondanza A; Sangiolo D
Oncoimmunology; 2018; 7(5):e1423167. PubMed ID: 29721373
[TBL] [Abstract][Full Text] [Related]
2. CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes.
Leuci V; Donini C; Grignani G; Rotolo R; Mesiano G; Fiorino E; Gammaitoni L; D'Ambrosio L; Merlini A; Landoni E; Medico E; Capellero S; Giraudo L; Cattaneo G; Iaia I; Pignochino Y; Basiricò M; Vigna E; Pisacane A; Fagioli F; Ferrone S; Aglietta M; Dotti G; Sangiolo D
Clin Cancer Res; 2020 Dec; 26(23):6321-6334. PubMed ID: 32900797
[TBL] [Abstract][Full Text] [Related]
3. CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma.
Giraudo L; Cattaneo G; Gammaitoni L; Iaia I; Donini C; Massa A; Centomo ML; Basiricò M; Vigna E; Pisacane A; Picciotto F; Berrino E; Marchiò C; Merlini A; Paruzzo L; Poletto S; Caravelli D; Biolato AM; Bortolot V; Landoni E; Ventin M; Ferrone CR; Aglietta M; Dotti G; Leuci V; Carnevale-Schianca F; Sangiolo D
J Exp Clin Cancer Res; 2023 Nov; 42(1):310. PubMed ID: 37993874
[TBL] [Abstract][Full Text] [Related]
4. Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children.
Merker M; Pfirrmann V; Oelsner S; Fulda S; Klingebiel T; Wels WS; Bader P; Rettinger E
Oncotarget; 2017 Sep; 8(39):66137-66153. PubMed ID: 29029499
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
6. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
[TBL] [Abstract][Full Text] [Related]
7. Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas.
Sangiolo D; Mesiano G; Gammaitoni L; Leuci V; Todorovic M; Giraudo L; Cammarata C; Dell'Aglio C; D'Ambrosio L; Pisacane A; Sarotto I; Miano S; Ferrero I; Carnevale-Schianca F; Pignochino Y; Sassi F; Bertotti A; Piacibello W; Fagioli F; Aglietta M; Grignani G
Cancer Res; 2014 Jan; 74(1):119-29. PubMed ID: 24356422
[TBL] [Abstract][Full Text] [Related]
8. CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma.
Ciulean IS; Fischer J; Quaiser A; Bach C; Abken H; Tretbar US; Fricke S; Koehl U; Schmiedel D; Grunwald T
Front Immunol; 2023; 14():1290488. PubMed ID: 38022580
[TBL] [Abstract][Full Text] [Related]
9. Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.
Mesiano G; Grignani G; Fiorino E; Leuci V; Rotolo R; D'Ambrosio L; Salfi C; Gammaitoni L; Giraudo L; Pisacane A; Butera S; Pignochino Y; Basiricó M; Capozzi F; Sapino A; Aglietta M; Sangiolo D
Oncoimmunology; 2018; 7(11):e1465161. PubMed ID: 30393581
[TBL] [Abstract][Full Text] [Related]
10. Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti-leukaemic potential and alloreactivity across major human leukocyte antigen barriers.
Circosta P; Donini C; Gallo S; Giraudo L; Gammaitoni L; Rotolo R; Galvagno F; Capellero S; Basiricò M; Casucci M; Aglietta M; Ferrero I; Fagioli F; Cignetti A; Carnevale-Schianca F; Leuci V; Sangiolo D
Br J Haematol; 2023 Jan; 200(1):64-69. PubMed ID: 36155897
[TBL] [Abstract][Full Text] [Related]
11. Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells.
Gammaitoni L; Giraudo L; Macagno M; Leuci V; Mesiano G; Rotolo R; Sassi F; Sanlorenzo M; Zaccagna A; Pisacane A; Senetta R; Cangemi M; Cattaneo G; Martin V; Coha V; Gallo S; Pignochino Y; Sapino A; Grignani G; Carnevale-Schianca F; Aglietta M; Sangiolo D
Clin Cancer Res; 2017 May; 23(9):2277-2288. PubMed ID: 27815354
[No Abstract] [Full Text] [Related]
12. Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy.
Marin V; Dander E; Biagi E; Introna M; Fazio G; Biondi A; D'Amico G
Exp Hematol; 2006 Sep; 34(9):1219-29. PubMed ID: 16939815
[TBL] [Abstract][Full Text] [Related]
13. Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition.
Wei F; Rong XX; Xie RY; Jia LT; Wang HY; Qin YJ; Chen L; Shen HF; Lin XL; Yang J; Yang S; Hao WC; Chen Y; Xiao SJ; Zhou HR; Lin TY; Chen YS; Sun Y; Yao KT; Xiao D
Oncotarget; 2015 Oct; 6(33):35023-39. PubMed ID: 26418951
[TBL] [Abstract][Full Text] [Related]
14. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia.
Linn YC; Hui KM
Leuk Lymphoma; 2003 Sep; 44(9):1457-62. PubMed ID: 14565644
[TBL] [Abstract][Full Text] [Related]
15. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
[TBL] [Abstract][Full Text] [Related]
16. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
17. In vitro comparison of three different chimeric receptor-modified effector T-cell populations for leukemia cell therapy.
Pizzitola I; Agostoni V; Cribioli E; Pule M; Rousseau R; Finney H; Lawson A; Biondi A; Biagi E; Marin V
J Immunother; 2011; 34(6):469-79. PubMed ID: 21654519
[TBL] [Abstract][Full Text] [Related]
18. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.
Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S
PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655
[TBL] [Abstract][Full Text] [Related]
19. Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol.
Rutella S; Iudicone P; Bonanno G; Fioravanti D; Procoli A; Lavorino C; Foddai ML; Lorusso D; Martinelli E; Vacca M; Ipsevich F; Nuti M; Scambia G; Pierelli L
Cytotherapy; 2012 Aug; 14(7):841-50. PubMed ID: 22563888
[TBL] [Abstract][Full Text] [Related]
20. [Construction of a new anti-CD123 chimeric antigen receptor T cells and effect of anti-acute myeloid leukemia].
Wang ZZ; Lu Y; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Xiong DS; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):192-197. PubMed ID: 32311887
[No Abstract] [Full Text] [Related]
[Next] [New Search]
